Erratum: Expression of Concern: MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC (PLoS ONE (2014) 9: 4 (e94639) DOi: 10.1371/journal.pone.0094639);miRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Jiang, Zeyong ^a   Yin, Jun ^a   Fu, Wenfan ^a   Mo, Yijun ^a   Pan, Youguang ^a   Dai, Lu ^a   Huang, Haoda ^a   Li, Siwen ^a   Zhao, Jian ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 17; MICRORNA 20A; MICRORNA 20B; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN17 MICRORNA, HUMAN; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CELL MIGRATION ASSAY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METASTASIS; MICROARRAY ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 84899581656     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0222896     Document Type: Erratum

References (33)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, et al. (2008) Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100: 1672-1694.
2. Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S, et al. (2013) Lung cancer biomarkers: State of the art. J Carcinog 12: 3.
3. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V (2012) Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 72: 4883-4889.
4. Mallini P, Lennard T, Kirby J, Meeson A (2014) Epithelial-to-mesenchymal transition: What is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 40: 341-348.
5. Tan J, You Y, Xu T, Yu P, Wu D, et al. (2013) Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicol Lett 224: 7-15.
6. Miyazono K (2009) Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 85: 314-323.
7. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
8. Edme N, Downward J, Thiery JP, Boyer B (2002) Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J Cell Sci 115: 2591-2601. (Pubitemid 34778076)
9. Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, et al. (2009) Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology 54: 442-451.
10. Nagathihalli NS, Merchant NB (2012) Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front Biosci (Landmark Ed) 17: 2059-2069.
11. Hills CE, Squires PE (2011) The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 22: 131-139.
12. Bi WR, Yang CQ, Shi Q (2012) Transforming growth factor-β1 induced epithelial-mesenchymal transition in hepatic fibrosis. Hepatogastroenterology 59: 1960-1963.
13. Iwano M (2010) EMT and TGF-beta in renal fibrosis. Front Biosci (Schol Ed) 2: 229-238.
14. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
15. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
16. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, et al. (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632. (Pubitemid 41541436)
17. Jin HY, Oda H, Lai M, Skalsky RL, Bethel K, et al. (2013) MicroRNA-17-92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J 32: 2377-2391.
18. Jevnaker AM, Khuu C, Kjøle E, Bryne M, Osmundsen H (2011) Expression of members of the miRNA17-92 cluster during development and in carcinogenesis. J Cell Physiol 226: 2257-2266.
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
20. Visbal AL, Leighl NB, Feld R, Shepherd FA (2005) Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest 128: 2933-2943. (Pubitemid 41507653)
21. Rudd R (1991) Chemotherapy in the treatment of non-small-lung cancer. Respiratory Disease in Practice 7: 12-14.
22. Reed JC (1999) Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11: 68-75.
23. Judson I, Kelland LR (2000) New developments and approaches in the platinum arena. Drugs 59 Suppl 4: 29-36; discussion 37-38.
24. Mestdagh P, Boström AK, Impens F, Fredlund E, Van Peer G, et al. (2010) The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell 40: 762-773.
25. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, et al. (2010) The myc-miR-17-92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 70: 8233-8246.
26. Olive V, Jiang I, He L (2010) mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42: 1348-1354.
27. Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, et al. (2013) Silencing of the miR-17-92 cluster family inhibits medulloblastoma progression. Cancer Res 73: 7068-7078.
28. Jevnaker AM, Khuu C, Kjøle E, Bryne M, Osmundsen H (2011) Expression of members of the miRNA17-92 cluster during development and in carcinogenesis. J Cell Physiol 226: 2257-2266.
29. Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M (2007) Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci 98: 1482-1490. (Pubitemid 47241774)
30. Chang CC, Yang YJ, Li YJ, Chen ST, Lin BR, et al. (2013) MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol 49: 923-931.
31. Geismann C, Morscheck M, Koch D, Bergmann F, Ungefroren H, et al. (2009) Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res 69: 4517-4526.
32. Clarke DC, Liu X (2008) Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol 18: 430-442.
33. Hills CE, Squires PE (2011) The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 22: 131-139.